Comparison of Low Dose Solifenacin and Mirabegron with Solifenacin Dose Escalation in Treatment of Overactive Bladder
Objective: The purpose of this study is to look into the efficacy and tolerability of 5mg monotherapy for OAB. In terms of outcomes and tolerability, the study will also compare the efficacy of solifenacin 10mg versus combinations of solifenacin 5mg/mirabegron 25 mg.
Methodology: This study was a comparative cross sectional study carried out in Ayub Teaching Hospital, Abbottabad, for a period of July, 2022 to October 2022. This was a double phase comparative study, conducted at the Ayub Teaching Hospital, Abbottabad. Female patients of aged ≥18 year with symptoms of OAB more than 3 months were enrolled in this study.
Results: The findings of current study showed that average age of patient was 37 ± 11.41 years. The study's population included 109 (100%) females. The duration of OAB was 5.12 ± 1.12, Number of incontinence episodes within 24 h as 4.78 ± 1.33, number of micturation’s within 24 h 7.01 ± 1.37, no of urgency episodes as 5.15 ± 0.97 and urgent Incontinence episodes/ 24 hours as 4.18 ± 1.25. After 3 weeks of follow up urgency incontinence episodes/ 24 hours 0.48 ± 0.70, nocturia episodes 0.73 ± 0.68, urgency episodes 1.44 ± 0. 50 and micturation episodes found in patients treated. Adverse events occurred during 3 weeks i.e., dizziness 7 (6.4%), dry mouth 3 (2.8%) and constipation 11 (10.1%). There was a significant difference in outcome nocturia episodes showing p-value 0.042. The study showed significant difference in tolerability and discontinuing treatment.
Conclusion: Mirabegron 25mg (M25 mg) plus solifenacin 5mg (S5 mg) improved OAB symptoms more than solifenacin 10mg (S10 mg), and it was well tolerated in OAB patients who remained incontinent after the initial solifenacin 5mg (S5 mg).
Copyright (c) 2023 Journal of The Society of Obstetricians and Gynaecologists of Pakistan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.